Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2025-12-30 @ 9:57 AM
Study NCT ID:
NCT00758160
Status:
COMPLETED
Last Update Posted:
2014-04-08
First Post:
2008-09-19
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001289', 'term': 'Attention Deficit Disorder with Hyperactivity'}], 'ancestors': [{'id': 'D019958', 'term': 'Attention Deficit and Disruptive Behavior Disorders'}, {'id': 'D065886', 'term': 'Neurodevelopmental Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'phone': '+886-2-23762155', 'title': 'Medical Affairs Director', 'organization': 'Janssen Pharmaceutical, Taiwan'}, 'certainAgreement': {'restrictionType': 'LTE60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'description': 'Adverse events(AEs) data was reported for each visit as total data for AEs were not analyzed. In addition to the AEs reported in the below table, a category of AEs titled "Other" was reported as no dictionary was used and events under this category were not further specified. Total # affected by other AEs is minimum number of participants affected.', 'eventGroups': [{'id': 'EG000', 'title': 'OROS MPH-Baseline', 'description': 'Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.', 'otherNumAtRisk': 296, 'otherNumAffected': 80, 'seriousNumAtRisk': 296, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'OROS MPH-Week 2', 'description': 'Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.', 'otherNumAtRisk': 296, 'otherNumAffected': 100, 'seriousNumAtRisk': 296, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'OROS MPH-Week 4', 'description': 'Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.', 'otherNumAtRisk': 296, 'otherNumAffected': 90, 'seriousNumAtRisk': 296, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'OROS MPH-Week 8', 'description': 'Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.', 'otherNumAtRisk': 296, 'otherNumAffected': 95, 'seriousNumAtRisk': 296, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Appetite decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 296, 'numAffected': 80}, {'groupId': 'EG001', 'numAtRisk': 296, 'numAffected': 100}, {'groupId': 'EG002', 'numAtRisk': 296, 'numAffected': 90}, {'groupId': 'EG003', 'numAtRisk': 296, 'numAffected': 95}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'No dictionary used'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 296, 'numAffected': 22}, {'groupId': 'EG001', 'numAtRisk': 296, 'numAffected': 22}, {'groupId': 'EG002', 'numAtRisk': 296, 'numAffected': 15}, {'groupId': 'EG003', 'numAtRisk': 296, 'numAffected': 15}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'No dictionary used'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 296, 'numAffected': 22}, {'groupId': 'EG001', 'numAtRisk': 296, 'numAffected': 35}, {'groupId': 'EG002', 'numAtRisk': 296, 'numAffected': 30}, {'groupId': 'EG003', 'numAtRisk': 296, 'numAffected': 25}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'No dictionary used'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 296, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 296, 'numAffected': 14}, {'groupId': 'EG002', 'numAtRisk': 296, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 296, 'numAffected': 7}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'No dictionary used'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 296, 'numAffected': 12}, {'groupId': 'EG001', 'numAtRisk': 296, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 296, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 296, 'numAffected': 9}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'No dictionary used'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 296, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 296, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 296, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 296, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'No dictionary used'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 296, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 296, 'numAffected': 20}, {'groupId': 'EG002', 'numAtRisk': 296, 'numAffected': 11}, {'groupId': 'EG003', 'numAtRisk': 296, 'numAffected': 12}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'No dictionary used'}, {'term': 'Stomachache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 296, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 296, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 296, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 296, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'No dictionary used'}, {'term': 'Other', 'stats': [{'groupId': 'EG000', 'numAtRisk': 296, 'numAffected': 26}, {'groupId': 'EG001', 'numAtRisk': 296, 'numAffected': 32}, {'groupId': 'EG002', 'numAtRisk': 296, 'numAffected': 25}, {'groupId': 'EG003', 'numAtRisk': 296, 'numAffected': 24}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'Other'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '296', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'OROS MPH', 'description': 'Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'classes': [{'title': 'Baseline: Inattention (n = 293)', 'categories': [{'measurements': [{'value': '1.7', 'spread': '0.6', 'groupId': 'OG000'}]}]}, {'title': 'Baseline: Hyperactivity (n = 293)', 'categories': [{'measurements': [{'value': '1.4', 'spread': '0.7', 'groupId': 'OG000'}]}]}, {'title': 'Baseline: Oppositional (n = 296)', 'categories': [{'measurements': [{'value': '1.3', 'spread': '0.7', 'groupId': 'OG000'}]}]}, {'title': 'Change at Week 2: Inattention (n = 293)', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '0.5', 'groupId': 'OG000'}]}]}, {'title': 'Change at Week 2: Hyperactivity (n = 293)', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '0.5', 'groupId': 'OG000'}]}]}, {'title': 'Change at Week 2: Oppositional (n = 296)', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '0.5', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 2', 'description': 'Parents were asked to assess their children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21. Mean Change was calculated as mean SNAP-IV score at Week 2 minus mean SNAP-IV score at Baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Intent-to-treat (ITT) analysis set included all participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. Here, 'n' included those participants who were evaluable for this measure at the specified time point."}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '296', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'OROS MPH', 'description': 'Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'classes': [{'title': 'Change at Week 4: Inattention (n = 293)', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '0.6', 'groupId': 'OG000'}]}]}, {'title': 'Change at Week 4: Hyperactivity (n = 293)', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '0.6', 'groupId': 'OG000'}]}]}, {'title': 'Change at Week 4: Oppositional (n = 296)', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '0.6', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4', 'description': 'Parents were asked to assess their children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21. Mean Change was calculated as mean SNAP-IV score at Week 4 minus mean SNAP-IV score at Baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT analysis set included all participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. Here, 'n' included those participants who were evaluable for this measure at the specified time point."}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '296', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'OROS MPH', 'description': 'Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'classes': [{'title': 'Change at Week 8: Inattention (n = 293)', 'categories': [{'measurements': [{'value': '-0.5', 'spread': '0.6', 'groupId': 'OG000'}]}]}, {'title': 'Change at Week 8: Hyperactivity (n = 293)', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '0.6', 'groupId': 'OG000'}]}]}, {'title': 'Change at Week 8: Oppositional (n = 296)', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '0.6', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 8', 'description': 'Parents were asked to assess their children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21. Mean Change was calculated as mean SNAP-IV score at Week 8 minus mean SNAP-IV score at Baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT analysis set included all participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. Here, 'n' included those participants who were evaluable for this measure at the specified time point."}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Chinese Health Questionnaire (CHQ) at Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '275', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'OROS MPH', 'description': 'Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'classes': [{'title': 'Baseline: Mother Assessment (n = 275)', 'categories': [{'measurements': [{'value': '1.9', 'spread': '0.6', 'groupId': 'OG000'}]}]}, {'title': 'Baseline: Father Assessment (n = 216)', 'categories': [{'measurements': [{'value': '1.7', 'spread': '0.4', 'groupId': 'OG000'}]}]}, {'title': 'Change at Week 4: Mother Assessment (n = 275)', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.4', 'groupId': 'OG000'}]}]}, {'title': 'Change at Week 4: Father Assessment (n = 216)', 'categories': [{'measurements': [{'value': '0', 'spread': '0.3', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4', 'description': "The CHQ is a self administered screening instrument used to assess psychiatric morbidity in the Chinese community. It was derived from the General Health Questionnaire, and has been validated with satisfactory construct validity and applied in the survey of psychiatric morbidity in the community and in hospital settings. Four factors are included in the structure: somatic symptoms; anxiety and worrying; sleep problems; and depression and poor family relationships. It contains 12 items, with a maximum score of 12. CHQ scores indicated the severity of participants' psychological problems (0-2=normal; 3-4=minor; 5-6=moderate; and 7-12=severe psychological problems). Mean Change was calculated as mean CHQ score at Week 4 minus mean CHQ score at Baseline.", 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT analysis set included parents of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point."}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Chinese Health Questionnaire (CHQ) at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '275', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'OROS MPH', 'description': 'Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'classes': [{'title': 'Change at Week 8: Mother Assessment (n = 275)', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.4', 'groupId': 'OG000'}]}]}, {'title': 'Change at Week 8: Father Assessment (n = 216)', 'categories': [{'measurements': [{'value': '0', 'spread': '0.4', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 8', 'description': "The CHQ is a self administered screening instrument used to assess psychiatric morbidity in the Chinese community. It was derived from the General Health Questionnaire, and has been validated with satisfactory construct validity and applied in the survey of psychiatric morbidity in the community and in hospital settings. Four factors are included in the structure: somatic symptoms; anxiety and worrying; sleep problems; and depression and poor family relationships. It contains 12 items, with a maximum score of 12. CHQ scores indicated the severity of participants' psychological problems (0-2=normal; 3-4=minor; 5-6=moderate; and 7-12=severe psychological problems). Mean Change was calculated as mean CHQ score at Week 8 minus mean CHQ score at Baseline.", 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT analysis set included parents of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point."}, {'type': 'SECONDARY', 'title': 'Chinese Version of the Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR-C) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '281', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'OROS MPH', 'description': 'Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'classes': [{'title': 'Baseline: Mother Assessment (n = 275)', 'categories': [{'measurements': [{'value': '6.4', 'spread': '2.9', 'groupId': 'OG000'}]}]}, {'title': 'Baseline: Father Assessment (n = 216)', 'categories': [{'measurements': [{'value': '6.5', 'spread': '2.5', 'groupId': 'OG000'}]}]}, {'title': 'Week 4: Mother Assessment (n = 280)', 'categories': [{'measurements': [{'value': '6.6', 'spread': '2.8', 'groupId': 'OG000'}]}]}, {'title': 'Week 4: Father Assessment (n = 223)', 'categories': [{'measurements': [{'value': '6.7', 'spread': '2.5', 'groupId': 'OG000'}]}]}, {'title': 'Week 8: Mother Assessment (n = 281)', 'categories': [{'measurements': [{'value': '6.5', 'spread': '3', 'groupId': 'OG000'}]}]}, {'title': 'Week 8: Father Assessment (n = 226)', 'categories': [{'measurements': [{'value': '6.6', 'spread': '2.7', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 4 and 8', 'description': 'Parents of the participants were asked to assess the Family APGAR which is a 5-item questionnaire designed to assess the 5 dimensions of perceived family support: Adaptation, Partnership, Growth, Affection, and Resolve. Each item is rated on a 3-point scale ranging from 0 to 2 where 0=hardly ever, 1=some of the time and 2=almost always. The total score ranges from 0 to 10 with greater scores indicating greater family support.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT analysis set included parents of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point."}, {'type': 'SECONDARY', 'title': 'Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Teachers) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '288', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'OROS MPH', 'description': 'Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'classes': [{'title': 'Baseline: Inattention (n = 281)', 'categories': [{'measurements': [{'value': '1.5', 'spread': '0.7', 'groupId': 'OG000'}]}]}, {'title': 'Baseline:Hyperactivity (n = 285)', 'categories': [{'measurements': [{'value': '1.1', 'spread': '0.7', 'groupId': 'OG000'}]}]}, {'title': 'Baseline: Oppositional (n = 283)', 'categories': [{'measurements': [{'value': '0.9', 'spread': '0.7', 'groupId': 'OG000'}]}]}, {'title': 'Week 2: Inattention (n = 286)', 'categories': [{'measurements': [{'value': '1.3', 'spread': '0.7', 'groupId': 'OG000'}]}]}, {'title': 'Week 2: Hyperactivity (n = 287)', 'categories': [{'measurements': [{'value': '0.9', 'spread': '0.7', 'groupId': 'OG000'}]}]}, {'title': 'Week 2: Oppositional (n = 286)', 'categories': [{'measurements': [{'value': '0.7', 'spread': '0.7', 'groupId': 'OG000'}]}]}, {'title': 'Week 4: Inattention (n = 287)', 'categories': [{'measurements': [{'value': '1.2', 'spread': '0.6', 'groupId': 'OG000'}]}]}, {'title': 'Week 4: Hyperactivity (n = 288)', 'categories': [{'measurements': [{'value': '0.9', 'spread': '0.8', 'groupId': 'OG000'}]}]}, {'title': 'Week 4: Oppositional (n = 287)', 'categories': [{'measurements': [{'value': '0.7', 'spread': '0.7', 'groupId': 'OG000'}]}]}, {'title': 'Week 8: Inattention (n = 287)', 'categories': [{'measurements': [{'value': '1.1', 'spread': '0.6', 'groupId': 'OG000'}]}]}, {'title': 'Week 8: Hyperactivity (n = 288)', 'categories': [{'measurements': [{'value': '0.8', 'spread': '0.7', 'groupId': 'OG000'}]}]}, {'title': 'Week 8: Oppositional (n = 287)', 'categories': [{'measurements': [{'value': '0.7', 'spread': '0.7', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4 and 8', 'description': 'Teachers were asked to assess the children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT analysis set included of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point."}, {'type': 'SECONDARY', 'title': 'Social Adjustment Scale Score for Children and Adolescents (SAICA)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '165', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'OROS MPH', 'description': 'Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'classes': [{'title': 'Baseline (n = 151)', 'categories': [{'measurements': [{'value': '1.5', 'spread': '0.7', 'groupId': 'OG000'}]}]}, {'title': 'Week 4 (n = 160)', 'categories': [{'measurements': [{'value': '1.8', 'spread': '0.3', 'groupId': 'OG000'}]}]}, {'title': 'Week 8 (n = 165)', 'categories': [{'measurements': [{'value': '1.8', 'spread': '0.3', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 4 and Week 8', 'description': "SAICA is a 77-item semi-structured interview scale designed for administration to school-aged children with age 6-18 years, or to their parents about their children. SAICA provides an evaluation of children's current functioning in the domains of school, spare time, peer relations, and home behaviors. Each item ranged on a 4-point likert scale ranging from 1 to 4 with a higher mean score indicating either poorer social function or a more severe social problem.", 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT analysis set included of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point."}, {'type': 'SECONDARY', 'title': 'Clinical Global Impression-Severity (CGI-S) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '292', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'OROS MPH', 'description': 'Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'classes': [{'title': 'Baseline (n = 290)', 'categories': [{'measurements': [{'value': '4.3', 'spread': '0.9', 'groupId': 'OG000'}]}]}, {'title': 'Week 2 (n = 291)', 'categories': [{'measurements': [{'value': '3.5', 'spread': '1.0', 'groupId': 'OG000'}]}]}, {'title': 'Week 4 (n = 291)', 'categories': [{'measurements': [{'value': '3.1', 'spread': '1.1', 'groupId': 'OG000'}]}]}, {'title': 'Week 8 (n = 292)', 'categories': [{'measurements': [{'value': '3.0', 'spread': '1.1', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4 and 8', 'description': "CGI-ADHD-S is a single item assessment of the global severity of ADHD symptoms in relation to the clinician's total experience after reviewing all the returned questionnaires and clinical assessment of participants' behavioral symptoms. Severity is rated on a 7-point scale ranging from 1 to 7 with 1=normal (not at all ill) and 7=most extremely ill.", 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT analysis set included of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point."}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinical Global Impression-Improvement (CGI-I) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '292', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'OROS MPH', 'description': 'Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'classes': [{'title': 'Week 2: Very much improved (n = 292)', 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}]}]}, {'title': 'Week 2: Much improved (n = 292)', 'categories': [{'measurements': [{'value': '98', 'groupId': 'OG000'}]}]}, {'title': 'Week 2: Minimally improved (n = 292)', 'categories': [{'measurements': [{'value': '126', 'groupId': 'OG000'}]}]}, {'title': 'Week 2: No change (n = 292)', 'categories': [{'measurements': [{'value': '45', 'groupId': 'OG000'}]}]}, {'title': 'Week 2: Minimally worse (n = 292)', 'categories': [{'measurements': [{'value': '16', 'groupId': 'OG000'}]}]}, {'title': 'Week 2: Much worse (n = 292)', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}]}]}, {'title': 'Week 2: Very much worse (n = 292)', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'Week 4: Very much improved (n = 262)', 'categories': [{'measurements': [{'value': '15', 'groupId': 'OG000'}]}]}, {'title': 'Week 4: Much improved (n = 262)', 'categories': [{'measurements': [{'value': '111', 'groupId': 'OG000'}]}]}, {'title': 'Week 4: Minimally improved (n = 262)', 'categories': [{'measurements': [{'value': '96', 'groupId': 'OG000'}]}]}, {'title': 'Week 4: No change (n = 262)', 'categories': [{'measurements': [{'value': '27', 'groupId': 'OG000'}]}]}, {'title': 'Week 4: Minimally worse (n = 262)', 'categories': [{'measurements': [{'value': '10', 'groupId': 'OG000'}]}]}, {'title': 'Week 4: Much worse (n = 262)', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}]}]}, {'title': 'Week 4: Very much worse (n = 262)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Week 8: Very much improved (n = 282)', 'categories': [{'measurements': [{'value': '16', 'groupId': 'OG000'}]}]}, {'title': 'Week 8: Much improved (n = 282)', 'categories': [{'measurements': [{'value': '129', 'groupId': 'OG000'}]}]}, {'title': 'Week 8: Minimally improved (n = 282)', 'categories': [{'measurements': [{'value': '91', 'groupId': 'OG000'}]}]}, {'title': 'Week 8: No change (n = 282)', 'categories': [{'measurements': [{'value': '28', 'groupId': 'OG000'}]}]}, {'title': 'Week 8: Minimally worse (n = 282)', 'categories': [{'measurements': [{'value': '13', 'groupId': 'OG000'}]}]}, {'title': 'Week 8: Much worse (n = 282)', 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}]}]}, {'title': 'Week 8: Very much worse (n = 282)', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 2, 4 and 8', 'description': "CGI-I is a single item assessment of the global improvement of ADHD symptoms in relation to the clinician's total experience after reviewing all the returned questionnaires and clinical assessment of participants' behavioral symptoms. Improvement is rated on a 7-point scale (1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse).", 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT analysis set included of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point."}, {'type': 'SECONDARY', 'title': 'Global Assessment of Satisfaction by Parents/Caregivers', 'denoms': [{'units': 'Participants', 'counts': [{'value': '291', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'OROS MPH', 'description': 'Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'classes': [{'title': 'Baseline (n = 290)', 'categories': [{'measurements': [{'value': '3.1', 'spread': '0.9', 'groupId': 'OG000'}]}]}, {'title': 'Week 2 (n = 291)', 'categories': [{'measurements': [{'value': '3.4', 'spread': '0.8', 'groupId': 'OG000'}]}]}, {'title': 'Week 4 (n = 291)', 'categories': [{'measurements': [{'value': '3.7', 'spread': '0.8', 'groupId': 'OG000'}]}]}, {'title': 'Week 8 (n = 291)', 'categories': [{'measurements': [{'value': '3.6', 'spread': '0.9', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4 and 8', 'description': 'Parents/caregivers were asked to assess the satisfaction with respect to ADHD treatment on a 5-point scale ranging from 1 to 5 where 1=completely dissatisfied, 2=somewhat dissatisfied, 3=neutral, 4=somewhat satisfied, and 5=completely satisfied.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT analysis set included of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point."}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Global Assessment of Satisfaction by Participant', 'denoms': [{'units': 'Participants', 'counts': [{'value': '291', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'OROS MPH', 'description': 'Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'classes': [{'title': 'Baseline (n = 290)', 'categories': [{'measurements': [{'value': '3.2', 'spread': '0.9', 'groupId': 'OG000'}]}]}, {'title': 'Week 2 (n = 291)', 'categories': [{'measurements': [{'value': '3.5', 'spread': '0.8', 'groupId': 'OG000'}]}]}, {'title': 'Week 4 (n = 291)', 'categories': [{'measurements': [{'value': '3.7', 'spread': '0.8', 'groupId': 'OG000'}]}]}, {'title': 'Week 8 (n = 291)', 'categories': [{'measurements': [{'value': '3.6', 'spread': '0.9', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 4 and 8', 'description': 'Participants were asked to assess their satisfaction with respect to ADHD treatment on a 5-point scale ranging from 1 to 5 where 1=completely dissatisfied, 2=somewhat dissatisfied, 3=neutral, 4=somewhat satisfied and 5=completely satisfied.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT analysis set included of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point."}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'OROS MPH', 'description': 'Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '296'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '230'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '66'}]}], 'dropWithdraws': [{'type': 'No Longer Requires Study Medication', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}]}, {'type': 'Administration Problems', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '15'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '10'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '14'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '12'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '8'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '296', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'OROS MPH', 'description': 'Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '9.5', 'spread': '2.4', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '49', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '247', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 296}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-03'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-03', 'completionDateStruct': {'date': '2008-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-03-10', 'studyFirstSubmitDate': '2008-09-19', 'resultsFirstSubmitDate': '2013-09-05', 'studyFirstSubmitQcDate': '2008-09-22', 'lastUpdatePostDateStruct': {'date': '2014-04-08', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2014-03-10', 'studyFirstPostDateStruct': {'date': '2008-09-23', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2014-04-08', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2008-06', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Global Assessment of Satisfaction by Participant', 'timeFrame': 'Baseline, Week 2, 4 and 8', 'description': 'Participants were asked to assess their satisfaction with respect to ADHD treatment on a 5-point scale ranging from 1 to 5 where 1=completely dissatisfied, 2=somewhat dissatisfied, 3=neutral, 4=somewhat satisfied and 5=completely satisfied.'}], 'primaryOutcomes': [{'measure': 'Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 2', 'timeFrame': 'Baseline and Week 2', 'description': 'Parents were asked to assess their children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21. Mean Change was calculated as mean SNAP-IV score at Week 2 minus mean SNAP-IV score at Baseline.'}, {'measure': 'Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 4', 'timeFrame': 'Baseline and Week 4', 'description': 'Parents were asked to assess their children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21. Mean Change was calculated as mean SNAP-IV score at Week 4 minus mean SNAP-IV score at Baseline.'}, {'measure': 'Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 8', 'timeFrame': 'Baseline and Week 8', 'description': 'Parents were asked to assess their children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21. Mean Change was calculated as mean SNAP-IV score at Week 8 minus mean SNAP-IV score at Baseline.'}, {'measure': 'Mean Change From Baseline in Chinese Health Questionnaire (CHQ) at Week 4', 'timeFrame': 'Baseline and Week 4', 'description': "The CHQ is a self administered screening instrument used to assess psychiatric morbidity in the Chinese community. It was derived from the General Health Questionnaire, and has been validated with satisfactory construct validity and applied in the survey of psychiatric morbidity in the community and in hospital settings. Four factors are included in the structure: somatic symptoms; anxiety and worrying; sleep problems; and depression and poor family relationships. It contains 12 items, with a maximum score of 12. CHQ scores indicated the severity of participants' psychological problems (0-2=normal; 3-4=minor; 5-6=moderate; and 7-12=severe psychological problems). Mean Change was calculated as mean CHQ score at Week 4 minus mean CHQ score at Baseline."}, {'measure': 'Mean Change From Baseline in Chinese Health Questionnaire (CHQ) at Week 8', 'timeFrame': 'Baseline and Week 8', 'description': "The CHQ is a self administered screening instrument used to assess psychiatric morbidity in the Chinese community. It was derived from the General Health Questionnaire, and has been validated with satisfactory construct validity and applied in the survey of psychiatric morbidity in the community and in hospital settings. Four factors are included in the structure: somatic symptoms; anxiety and worrying; sleep problems; and depression and poor family relationships. It contains 12 items, with a maximum score of 12. CHQ scores indicated the severity of participants' psychological problems (0-2=normal; 3-4=minor; 5-6=moderate; and 7-12=severe psychological problems). Mean Change was calculated as mean CHQ score at Week 8 minus mean CHQ score at Baseline."}], 'secondaryOutcomes': [{'measure': 'Chinese Version of the Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR-C) Score', 'timeFrame': 'Baseline, Week 4 and 8', 'description': 'Parents of the participants were asked to assess the Family APGAR which is a 5-item questionnaire designed to assess the 5 dimensions of perceived family support: Adaptation, Partnership, Growth, Affection, and Resolve. Each item is rated on a 3-point scale ranging from 0 to 2 where 0=hardly ever, 1=some of the time and 2=almost always. The total score ranges from 0 to 10 with greater scores indicating greater family support.'}, {'measure': 'Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Teachers) Score', 'timeFrame': 'Baseline, Week 2, 4 and 8', 'description': 'Teachers were asked to assess the children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21.'}, {'measure': 'Social Adjustment Scale Score for Children and Adolescents (SAICA)', 'timeFrame': 'Baseline, Week 4 and Week 8', 'description': "SAICA is a 77-item semi-structured interview scale designed for administration to school-aged children with age 6-18 years, or to their parents about their children. SAICA provides an evaluation of children's current functioning in the domains of school, spare time, peer relations, and home behaviors. Each item ranged on a 4-point likert scale ranging from 1 to 4 with a higher mean score indicating either poorer social function or a more severe social problem."}, {'measure': 'Clinical Global Impression-Severity (CGI-S) Score', 'timeFrame': 'Baseline, Week 2, 4 and 8', 'description': "CGI-ADHD-S is a single item assessment of the global severity of ADHD symptoms in relation to the clinician's total experience after reviewing all the returned questionnaires and clinical assessment of participants' behavioral symptoms. Severity is rated on a 7-point scale ranging from 1 to 7 with 1=normal (not at all ill) and 7=most extremely ill."}, {'measure': 'Number of Participants With Clinical Global Impression-Improvement (CGI-I) Score', 'timeFrame': 'Baseline, Week 2, 4 and 8', 'description': "CGI-I is a single item assessment of the global improvement of ADHD symptoms in relation to the clinician's total experience after reviewing all the returned questionnaires and clinical assessment of participants' behavioral symptoms. Improvement is rated on a 7-point scale (1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse)."}, {'measure': 'Global Assessment of Satisfaction by Parents/Caregivers', 'timeFrame': 'Baseline, Week 2, 4 and 8', 'description': 'Parents/caregivers were asked to assess the satisfaction with respect to ADHD treatment on a 5-point scale ranging from 1 to 5 where 1=completely dissatisfied, 2=somewhat dissatisfied, 3=neutral, 4=somewhat satisfied, and 5=completely satisfied.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Attention Deficit Disorder With Hyperactivity', 'Methylphenidate', 'Concerta'], 'conditions': ['Attention Deficit Disorder With Hyperactivity']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate whether familial relationships and psychological status of participants or caregivers as well as Attention Deficit Hyperactivity Disorder (ADHD) symptoms of participants can be improved by switching from Immediate-release Methylphenidate (IR-MPH) to Osmotic Release Oral Delivery System Methylphenidate (OROS-MPH).', 'detailedDescription': "This is a prospective (study following participants forward in time), single-arm, open-label (all people know the identity of the intervention), 8-week, multi-centric (conducted in more than 1 center) study. OROS-MPH will be administered orally for 2 months at doses of 18, 36, or 54 milligram (mg) to replace IR-MPH. Clinicians will adjust the dose of each participant according to participant's clinical responses and/or side effects. During the study period, participants will be assessed on Week 2, 4, and 8. Efficacy will be evaluated primarily based on change from baseline in Chinese version of the 26-item Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) rating scale assessed by parents and Chinese Health Questionnaire (CHQ). Safety will be monitored throughout the study."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '18 Years', 'minimumAge': '6 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Participants who are diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)\n* Participants who have been treated with Immediate-release methyphenidate (IR-MPH) for at least 4 weeks before enrollment, but previous treatment is considered unsatisfactory due to 1 or more of the following reasons: lack of effectiveness, lack of tolerability or safety, lack of compliance, and/or other reasons\n* Participants who are able to comply with the study visit schedule and whose parents/caregiver and community school teacher are willing and able to complete the protocol-specified assessments\n* Participants who are still at school\n* Participants who are treated with greater than equal to 10 milligram (mg) IR-MPH daily before enrollment\n\nExclusion Criteria:\n\n* Participants who cannot understand or follow the instructions given in the study\n* Participants with serious or unstable medical illness\n* Participants who have clinically significant gastrointestinal problems, including narrowing of the gastrointestinal tract\n* Participants who have glaucoma (increased pressure inside the eye that causes visual problems), an ongoing seizure disorders, or a psychotic disorder\n* Participants who are hypersensitive to methylphenidate\n* Participants who have any co-existing medical condition or are taking a concomitant medication that is likely to interfere with safe administration of methylphenidate'}, 'identificationModule': {'nctId': 'NCT00758160', 'briefTitle': 'The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Johnson & Johnson Taiwan Ltd'}, 'officialTitle': 'From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD', 'orgStudyIdInfo': {'id': 'CR015331'}, 'secondaryIdInfos': [{'id': 'CONCERTAATT4086'}, {'id': 'CCT-TWN-MA6'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'OROS methylphenidate', 'description': 'Participants willl receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.', 'interventionNames': ['Drug: OROS Methylphenidate']}], 'interventions': [{'name': 'OROS Methylphenidate', 'type': 'DRUG', 'description': 'Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.', 'armGroupLabels': ['OROS methylphenidate']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Johnson & Johnson Taiwan, Ltd. Clinical Trial', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Johnson & Johnson Taiwan Ltd'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Johnson & Johnson Taiwan Ltd', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}